Clinical Trial Update: Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-7684A-007/KEYVIBE-007 comparing pembrolizumab/vibostolimab coformulation plus chemotherapy to pembrolizumab plus chemotherapy in metastatic non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MK-7684A (pembrolizumab/vibostolimab) coformulation
• Vibostolimab (vibostolimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-11-13